Global CD70-Targeting Therapies Market Report 2026 - Highlights Clinical Innovation, Pipeline Trends And Commercial Opportunities
Dublin, Aug. 27, 2026 (GLOBE NEWSWIRE) -- The "Global CD70 Targeting Therapies Clinical Innovation, Market Trends, Therapeutic Approaches, Technology Platforms & Clinical Trials Insight 2026" has been added to ResearchAndMarkets.com's offering.
Thereport provides a comprehensive assessment of the rapidly evolving CD70-targeting therapies market. Covering clinical development, technology platforms, regulatory designations, competitive activity and regional trends, the report offers strategic intelligence for pharmaceutical companies, biotechnology firms, investors, researchers and other stakeholders in precision oncology and immunotherapy.
Key findings and report highlights:
- First approval of a CD70-targeted therapy anticipated by 2032 Phase II identified as the highest current stage of clinical development More than 30 CD70-targeting therapies assessed across the clinical pipeline Clinical trial analysis by company, country, indication and development phase Assessment of FDA and EMA designations, including Orphan Drug, Fast Track and Regenerative Medicine Advanced Therapy designations Company-level analysis of CD70 technology development platforms Detailed competitive landscape and future market outlook
Growing Need for CD70-Targeted Therapies
CD70 has emerged as a significant therapeutic target in precision oncology and next-generation immunotherapy because of its expression across hematological malignancies and selected solid tumors, together with comparatively limited expression in healthy tissues. This profile has encouraged the development of selective therapeutic candidates designed to improve antitumor activity while reducing systemic toxicity.
The CD70-targeting therapies pipeline includes monoclonal antibodies, antibody-drug conjugates, bispecific and multispecific antibodies, CAR-T cell therapies, CAR-NK cell therapies and other immune cell-based approaches. Scientific and commercial interest is also expanding beyond oncology into autoimmune and inflammatory diseases, creating additional opportunities for research, clinical development and long-term market growth.
CD70-Targeting Therapies Clinical Pipeline Analysis
The report evaluates more than 30 CD70-targeting therapies across preclinical studies and Phase I, Phase I/II and Phase II clinical trials. Pipeline programs are assessed across major indications, including acute myeloid leukemia, lymphoma, renal cell carcinoma, gynecological cancers, lung cancer, autoimmune disorders, inflammatory conditions and other CD70-positive malignancies.
Clinical development activity increasingly includes combination regimens involving immunotherapies, epigenetic inhibitors, chemotherapy and targeted agents. These strategies are intended to strengthen treatment responses, broaden eligible patient populations and address resistance mechanisms. The report also examines biomarker-driven development and patient-selection strategies that could support more precise clinical positioning.
Competitive Landscape and Leading Companies
The global CD70-targeting therapies competitive landscape includes established pharmaceutical companies, emerging biotechnology businesses, academic institutions and specialist cancer research centers. Companies active in the field include Allogene Therapeutics, OncoVerity, Ambrx, a Johnson & Johnson company, Molecular Partners and CRISPR Therapeutics, among others.
These organizations are advancing differentiated programs through proprietary platforms, distinct mechanisms of action and varied clinical development strategies. Academic and research institutions are also contributing to target validation, translational research and early-stage innovation, supporting the continued expansion of the global CD70 therapy pipeline.
Technology Platforms, Collaborations and Agreements
Technology innovation is a central feature of CD70 drug development. Platforms covered in the report include proprietary antibody engineering, allogeneic cell therapy manufacturing, gamma delta cell technologies, designed ankyrin repeat protein platforms and Potelligent antibody engineering. The analysis compares company-specific platforms and evaluates their potential influence on efficacy, safety, scalability and product differentiation.
Strategic collaborations among biotechnology companies, pharmaceutical manufacturers and research institutions are accelerating drug discovery, manufacturing and clinical development. Such partnerships are also creating opportunities for licensing, co-development, regional commercialization and pipeline expansion.
Future Outlook for the CD70-Targeting Therapies Market
The future of CD70-targeted therapy is expected to be shaped by combination regimens, engineered immune cell therapies, multispecific antibodies, next-generation antibody-drug conjugates and biomarker-led precision medicine. As additional candidates progress through clinical trials and regulatory review, commercialization opportunities are expected to expand across the United States, China and Europe.
The report delivers forward-looking insight into CD70 clinical trials, regulatory pathways, competitive positioning and market development. It enables stakeholders to identify emerging opportunities, evaluate technology platforms, monitor leading pipeline programs and prepare for the next phase of innovation in the global CD70-targeting therapies market.
Key Topics Covered
1. Research Methodology
2. Introduction to CD70 Targeting Therapy
2.1 CD70 Targeting Therapy Overview
2.2 Dual Role of CD70 as Diagnostic & Prognostic Biomarker
3. CD70 Targeting Therapeutic Approaches
3.1 Monoclonal Antibody
3.2 Bispecific Antibody
3.3 Tetraspecific Antibody
3.4 CAR T Cell Therapy
3.5 Antibody Drug Conjugate
3.6 CAR-NK Therapy
4. CD70 Targeting Therapies Technology Development Platforms by Company
5. Global CD70 Targeting Therapies Current Market Trend & Developments
5.1 Current Market Outline
5.2 Future Market Forecast
5.3 Regulatory Designations: Fast Track & Orphan Designation
6. CD70 Targeting Therapies Market Opportunity & Clinical Trends by Region
6.1 US
6.2 China
6.3 Europe
7. CD70 Targeting Therapies Clinical Research & Innovation by Indications
7.1 Leukemia
7.2 Lymphoma
7.3 Gynecologic Cancer
7.4 Renal Cell Carcinoma
7.5 Lung Cancer
7.6 Autoimmune & Inflammatory Disease
7.7 Viral Infections
8. Global CD70 Targeting Therapies Clinical Trials Overview
8.1 by Phase
8.2 by Country
8.3 by Company
8.4 by Indication
8.5 by Priority Status
9. Global CD70 Targeting Therapies Clinical Trials Insight by Company, Country, Indication & Phase
9.1 Research
9.2 Preclinical
9.3 Phase I
9.4 Phase I/II
9.5 Phase II
10. Combination Strategies for CD70 Targeting Therapies
10.1 In Combination with Immunotherapy
10.2 In Combination with Epigenetic Modulators
10.3 In Combination with Targeted Therapy
10.4 In Combination with Oncolytic Virus Therapy
10.5 In Combination with Chemotherapy
11. Global CD70 Targeting Therapies Market Dynamics
11.1 Market Drivers
11.2 Market Challenges
12. Competitive Landscape
12.1 Adaptimmune
12.2 Allogene Therapeutics
12.3 Ambrx (Johnson & Johnson)
12.4 Chongqing Precision Biotech
12.5 CRISPR Therapeutics
12.6 ImmuneOnco Biopharma
12.7 Molecular Partners
12.8 Pfizer
12.9 Poseida Therapeutics
12.10 Shenzhen Geno-Immune Medical Institute
List of Figures
Figure 2-1: Introduction To CD70 Protein
Figure 2-2: History & Development Of CD70 Targeting Therapies
Figure 2-3: CD70 As Diagnostic & Prognostic Marker In Cancer
Figure 3-1: Approaches For Targeting CD70
Figure 4-1: Allogene Therapeutics - AlloCAR T Platform
Figure 4-2: Adicet Bio - Gamma Delta Cell Platform
Figure 4-3: ADI-270 - CD70 CAR?? T Cell Therapy
Figure 4-4: Catamaran Bio - Tailwind Platform
Figure 4-5: Molecular Partners - DARPin Platform
Figure 4-6: Nkarta - CAR-NK Cells
Figure 4-7: Nkarta - Proprietary CAR-NK Cells Manufacturing Process
Figure 5-1: CD70 Targeting Therapy Current Market - Guiding Factors
Figure 5-2: Key Players In CD70 Market
Figure 5-3: CD70 Targeting Therapy Market Future - Influencing Factors
Figure 7-1: Role Of CD70 In Leukemia
Figure 7-2: Molecular Partners - MP0533
Figure 7-3: MP0533-CP101 Phase I/II (NCT05673057) Study - Initiation & Completion Year
Figure 7-4: CULMINATE Phase II (NCT04023526) Study - Initiation & Completion Year
Figure 7-5: OV-AML-1231 Phase II (NCT06384261) Study - Initiation & Completion Year
Figure 7-6: Role Of CD70 In Leukemia
Figure 7-7: NCI-2021-12093 Phase I/II (NCT05092451) Study - Initiation & Completion Year
Figure 7-8: 2022-088 Phase I (NCT05667155) Study - Initiation & Completion Year
Figure 7-9: CD70 CAR T Therapy Early Phase I (NCT04662294) Study - Initiation & Completion Year
Figure 7-10: Lymphoma: Key Market Players Conducting CD70 Clinical Research
Figure 7-11: Role Of CD70 In Gynecologic Cancers
Figure 7-12: PBC052 CAR-T Therapy Phase I (NCT06010875) Study - Initiation & Completion Year
Figure 7-13: 16-C-0131 Phase I/II (NCT02830724) Study - Initiation & Completion Year
Figure 7-14: Role Of CD70 In Renal Cell Carcinoma
Figure 7-15: Research by Allogene Therapeutics
Figure 7-16: TRAVERSE Phase 1 (NCT04696731) Study - Initiation & Completion Year
Figure 7-17: Role Of CD70 In Lung Cancer
Figure 7-18: Role Of CD70 In Autoimmune & Inflammatory Diseases
Figure 7-19: RESOLUTION Phase 1 (NCT07085104) Study - Initiation & Completion Year
Figure 7-20: PBC103 Phase 1 (NCT07184450) Study - Initiation & Completion Year
Figure 7-21: PBC088 Phase 1 (NCT06934447) Study - Initiation & Completion Year
Figure 7-22: Role Of CD70 In Autoimmune & Inflammatory Diseases
Figure 8-1: Global - Number Of CD70 Targeting Therapies in Clinical Trials by Phase, 2026
Figure 8-2: Global - Number Of CD70 Targeting Therapies In Clinical Trials by Country, 2026
Figure 8-3: Global - Number Of CD70 Targeting Therapies In Clinical Trials by Company, 2026
Figure 8-4: Global - Number Of CD70 Targeting Therapies In Clinical Trials by Indication, 2026
Figure 8-5: Global - Number Of CD70 Targeting Therapies In Clinical Trials by Priority Status, 2026
Figure 10-1: Combinations Of CD70 Therapy With Other Therapies
Figure 11-1: Global CD70 Targeting Therapy Market - Drivers
Figure 11-2: Global CD70 Targeting Therapy Market - Challenges
List of Tables
Table 5-1: CD70 Targeting Therapies With Regulatory Designations
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment